<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">mCgYQVGSn7sHdwKmcQfFskP</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2012001000011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(12)09900100011</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2012005000053</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rela&#231;&#227;o entre a Escala de Ades&#227;o Terap&#234;utica de oito itens de Morisky (MMAS-8) e o controle da press&#227;o arterial</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira-Filho</surname>
            <given-names>Alfredo Dias</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barreto-Filho</surname>
            <given-names>Jos&#233; Augusto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Neves</surname>
            <given-names>Sabrina Joany Felizardo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lyra Junior</surname>
            <given-names>Divaldo Pereira de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">Sergipe</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de Sergipe</institution>
        <institution content-type="orgdiv1">Curso de Farm&#225;cia </institution>
        <institution content-type="orgdiv2">Laborat&#243;rio de Ensino e Pesquisa em Farm&#225;cia Social</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="state">Sergipe</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de Sergipe</institution>
        <institution content-type="orgdiv1">Departamento de Medicina </institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="state">Alagoas</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de Alagoas</institution>
        <institution content-type="orgdiv1">Departamento de Farm&#225;cia e Nutri&#231;&#227;o </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>07</month>
        <year>2012</year>
      </pub-date>
      <volume>99</volume>
      <issue>1</issue>
      <fpage>649</fpage>
      <lpage>658</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>07</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>01</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>11</day>
          <month>08</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A n&#227;o ades&#227;o terap&#234;utica &#233; um importante e frequentemente n&#227;o reconhecido fator de risco que contribui para o reduzido controle da Press&#227;o Arterial (PA). OBJETIVO: Determinar a rela&#231;&#227;o entre a ades&#227;o terap&#234;utica mensurada a partir de uma vers&#227;o validada em portugu&#234;s da MMAS-8 e o controle da PA em pacientes ambulatoriais hipertensos. M&#201;TODOS: Foi realizado um estudo transversal com pacientes hipertensos maiores de 18 anos atendidos em seis unidades da Estrat&#233;gia de Sa&#250;de da Fam&#237;lia, em Macei&#243; (AL), por meio de entrevistas e mensura&#231;&#227;o da press&#227;o arterial em domic&#237;lio, entre janeiro e abril de 2011. A ades&#227;o foi determinada por meio de vers&#227;o da MMAS-8 traduzida para realiza&#231;&#227;o deste estudo. Foram considerados aderentes aqueles pacientes com pontua&#231;&#227;o igual a 8 na MMAS-8. RESULTADOS: A preval&#234;ncia da ades&#227;o terap&#234;utica entre os 223 pacientes investigados foi de 19,7%, enquanto 34% apresentaram PA controlada (&gt; 140/90 mmHg). O valor m&#233;dio de ades&#227;o segundo a MMAS-8 foi 5,8 (&#177;1,8). Os pacientes aderentes se revelaram mais propensos (OR = 6,1; IC [95%] = 3,0 a 12,0) a ter a press&#227;o arterial sob controle do que aqueles que atingiram valores m&#233;dios (6 a &lt;8) ou baixos (&lt;6) no score de ades&#227;o. A vers&#227;o em portugu&#234;s da MMAS-8 apresentou associa&#231;&#227;o significativa com o controle da PA (p = 0,000). CONCLUS&#195;O: O diagn&#243;stico do comportamento n&#227;o aderente por meio da aplica&#231;&#227;o da MMAS-8 em pacientes sob uso de medicamentos anti-hipertensivos foi fator preditivo de valores elevados de PA sist&#243;lica e diast&#243;lica.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>ades&#227;o &#224; medica&#231;&#227;o</kwd>
        <kwd>press&#227;o arterial</kwd>
        <kwd>pacientes ambulatoriais</kwd>
        <kwd>sistema de sa&#250;de</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>07</day>
        <month>06</month>
        <year>2012</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>Rela&#231;&#227;o entre a Escala de Ades&#227;o Terap&#234;utica de oito itens de Morisky (MMAS-8) e o controle da press&#227;o arterial </bold>
    </p>
    <p>
      <bold>Alfredo Dias Oliveira-Filho; Jos&#233; Augusto Barreto-Filho; Sabrina Joany Felizardo Neves; Divaldo Pereira de Lyra Junior</bold>
    </p>
    <p>Laborat&#243;rio de Ensino e Pesquisa em Farm&#225;cia Social (LEPFS), Curso de Farm&#225;cia, Universidade Federal de Sergipe, Departamento de Farm&#225;cia e Nutri&#231;&#227;o, Universidade Federal de Alagoas, Departamento de Medicina, Universidade Federal de Sergipe, SE - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold> FUNDAMENTO:</bold> A n&#227;o ades&#227;o terap&#234;utica &#233; um importante e frequentemente n&#227;o reconhecido fator de risco que contribui para o reduzido controle da Press&#227;o Arterial (PA). </p>
    <p><bold>OBJETIVO:</bold> Determinar a rela&#231;&#227;o entre a ades&#227;o terap&#234;utica mensurada a partir de uma vers&#227;o validada em portugu&#234;s da MMAS-8 e o controle da PA em pacientes ambulatoriais hipertensos. </p>
    <p><bold> M&#201;TODOS:</bold> Foi realizado um estudo transversal com pacientes hipertensos maiores de 18 anos atendidos em seis unidades da Estrat&#233;gia de Sa&#250;de da Fam&#237;lia, em Macei&#243; (AL), por meio de entrevistas e mensura&#231;&#227;o da press&#227;o arterial em domic&#237;lio, entre janeiro e abril de 2011. A ades&#227;o foi determinada por meio de vers&#227;o da MMAS-8 traduzida para realiza&#231;&#227;o deste estudo. Foram considerados aderentes aqueles pacientes com pontua&#231;&#227;o igual a 8 na MMAS-8. </p>
    <p><bold>RESULTADOS:</bold> A preval&#234;ncia da ades&#227;o terap&#234;utica entre os 223 pacientes investigados foi de 19,7%, enquanto 34% apresentaram PA controlada (&gt; 140/90 mmHg). O valor m&#233;dio de ades&#227;o segundo a MMAS-8 foi 5,8 (&#177;1,8). Os pacientes aderentes se revelaram mais propensos (OR = 6,1; IC [95%] = 3,0 a 12,0) a ter a press&#227;o arterial sob controle do que aqueles que atingiram valores m&#233;dios (6 a &lt;8) ou baixos (&lt;6) no score de ades&#227;o. A vers&#227;o em portugu&#234;s da MMAS-8 apresentou associa&#231;&#227;o significativa com o controle da PA (p = 0,000). </p>
    <p><bold>CONCLUS&#195;O:</bold> O diagn&#243;stico do comportamento n&#227;o aderente por meio da aplica&#231;&#227;o da MMAS-8 em pacientes sob uso de medicamentos anti-hipertensivos foi fator preditivo de valores elevados de PA sist&#243;lica e diast&#243;lica. </p>
    <p><bold>Palavras-chave:</bold> ades&#227;o &#224; medica&#231;&#227;o; press&#227;o arterial; pacientes ambulatoriais; sistema de sa&#250;de.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Em pacientes com Hipertens&#227;o Arterial Sist&#234;mica (HAS), a n&#227;o ades&#227;o terap&#234;utica &#233; um importante e frequentemente n&#227;o reconhecido fator de risco que contribui para o reduzido controle da Press&#227;o Arterial (PA), levando ao desenvolvimento de outras doen&#231;as cardiovasculares, tais como insufici&#234;ncia card&#237;aca, doen&#231;a arterial coronariana, insufici&#234;ncia renal e acidente vascular cerebral<sup>1</sup>.</p>
    <p>Estudos abrangendo cinco d&#233;cadas estimam que 20% a 50% dos pacientes n&#227;o tomam seus medicamentos de acordo com a prescri&#231;&#227;o<sup>2</sup>. Segundo a Organiza&#231;&#227;o Mundial de Sa&#250;de (OMS), em pa&#237;ses desenvolvidos, a n&#227;o ades&#227;o em pacientes com doen&#231;as cr&#244;nicas oscila em torno de 50%, sendo provavelmente maior nos pa&#237;ses em desenvolvimento<sup>3</sup>.</p>
    <p>Embora a preval&#234;ncia e as implica&#231;&#245;es da n&#227;o ades&#227;o sobre os desfechos cl&#237;nicos venham se tornando cada vez mais reconhecidas, o verdadeiro impacto de medidas reconhecidamente efetivas no controle da PA, como o acesso gratuito &#224; farmacoterapia provido em n&#237;vel ambulatorial pelo Sistema &#218;nico de Sa&#250;de (SUS), em especial por meio da Estrat&#233;gia de Sa&#250;de da Fam&#237;lia, ainda &#233; ignorado<sup>4</sup>. Desse modo, a sistematiza&#231;&#227;o do diagn&#243;stico de n&#227;o ades&#227;o &#233; fundamental para a investiga&#231;&#227;o do seu impacto nos desfechos cl&#237;nicos. </p>
    <p>Nesse contexto, um dos m&#233;todos de determina&#231;&#227;o da ades&#227;o mais usados &#233; a Escala de Ades&#227;o Terap&#234;utica de Morisky de quatro Itens (MMAS-4)<sup>5</sup>. Recentemente, uma nova escala de oito itens (MMAS-8) e com maior confiabilidade (a = 0,83 vs a = 0,61)<sup>6</sup>, criada com o objetivo de determinar a ades&#227;o a tratamentos anti-hipertensivos, foi desenvolvida a partir da MMAS-4 e complementada com itens adicionais delineados para abordar v&#225;rios aspectos do comportamento aderente. No Brasil, estudos avaliando a n&#227;o ades&#227;o com a nova escala ainda s&#227;o recentes e escassos<sup>7</sup>.</p>
    <p>O presente estudo teve como objetivo determinar a rela&#231;&#227;o entre a ades&#227;o terap&#234;utica mensurada a partir de uma vers&#227;o validada em portugu&#234;s da MMAS-8 e o controle da PA em pacientes ambulatoriais hipertensos atendidos pela Estrat&#233;gia de Sa&#250;de da Fam&#237;lia.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Delineamento, locais e per&#237;odo do estudo</bold>
    </p>
    <p>Foi realizado um estudo transversal por meio da aplica&#231;&#227;o de entrevista estruturada a pacientes com hipertens&#227;o atendidos pela Estrat&#233;gia de Sa&#250;de da Fam&#237;lia. As entrevistas ocorreram em seis Unidades de Sa&#250;de da Fam&#237;lia (USF) de Macei&#243; vinculadas &#224; segunda edi&#231;&#227;o do Programa de Educa&#231;&#227;o Tutorial em Sa&#250;de (PET-Sa&#250;de II), entre janeiro e abril de 2011.</p>
    <p>
      <bold>Popula&#231;&#227;o do estudo</bold>
    </p>
    <p>Foram selecionados pacientes com diagn&#243;stico confirmado de hipertens&#227;o arterial sist&#234;mica cadastrados nas referidas USF, com dezoito anos ou mais e em uso de medicamentos anti-hipertensivos. Foram exclu&#237;dos pacientes com hipertens&#227;o secund&#225;ria confirmada em prontu&#225;rio ou que compraram pelo menos um medicamento anti-hipertensivo nos trinta dias anteriores &#224; entrevista. Esse crit&#233;rio de exclus&#227;o teve como finalidade eliminar a interfer&#234;ncia do custo dos medicamentos, considerado um dos principais fatores preditivos da n&#227;o ades&#227;o<sup>8</sup>. </p>
    <p>
      <bold>Entrevistas e vari&#225;veis avaliadas</bold>
    </p>
    <p>As entrevistas foram realizadas no domic&#237;lio do paciente, por acad&#234;micos de Farm&#225;cia previamente treinados, integrantes do PET-Sa&#250;de, acompanhados durante a visita domiciliar por um agente de sa&#250;de da USF. Foram investigadas as seguintes vari&#225;veis independentes: g&#234;nero, idade, escolaridade, pr&#225;tica de atividade f&#237;sica regular, consumo de bebidas alco&#243;licas, tabagismo, medicamentos, quantidade de medicamentos, tempo de uso dos anti-hipertensivos, Press&#227;o Arterial Sist&#243;lica (PAS), Press&#227;o Arterial Diast&#243;lica (PAD) e controle da press&#227;o arterial, caracterizada por valores de PA &lt; 140/90 mmHg, respectivamente.</p>
    <p>Os pacientes com press&#227;o arterial n&#227;o controlada foram classificados como pacientes com hipertens&#227;o resistente ou com hipertens&#227;o pseudorresistente, de acordo com a literatura<sup>9-11</sup>. Os valores de Press&#227;o Arterial Sist&#243;lica (PAS) e Diast&#243;lica (PAD) foram obtidos por meio da m&#233;dia de duas medidas da press&#227;o arterial, realizadas pela equipe de pesquisa durante a visita, de acordo com as orienta&#231;&#245;es estabelecidas nas VI Diretrizes Brasileiras para o Tratamento da Hipertens&#227;o Arterial<sup>9</sup>, utilizando-se esfigmoman&#244;metros de coluna de merc&#250;rio calibrados, com intervalo m&#237;nimo de 5 minutos entre cada medida. Para reduzir a interfer&#234;ncia do efeito do jaleco branco - definido como uma press&#227;o arterial persistentemente aumentada no consult&#243;rio m&#233;dico em compara&#231;&#227;o com medidas domiciliares ou ap&#243;s 24 horas de monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial (MAPA) - sobre a leitura dos valores de PA, as medidas ocorreram nos domic&#237;lios dos pacientes<sup>12,13</sup>.</p>
    <p>A ades&#227;o terap&#234;utica foi determinada por meio da Escala de Ades&#227;o Terap&#234;utica de Morisky de oito itens, vers&#227;o em portugu&#234;s (<xref ref-type="fig" rid="quad1">quadro 1</xref>) da Morisky Medication Adherence Scale (MMAS-8)<sup>6</sup>, traduzida e validada para realiza&#231;&#227;o do presente estudo. Para obten&#231;&#227;o da equival&#234;ncia conceitual, a MMAS-8 foi traduzida de acordo com as recomenda&#231;&#245;es para tradu&#231;&#227;o e adapta&#231;&#227;o transcultural de Beaton e cols.<sup>14</sup> Wild e cols.<sup>15</sup>, que requerem a tradu&#231;&#227;o e a retrotradu&#231;&#227;o por tradutores bil&#237;ngues, alguns dos quais independentes. Ap&#243;s avalia&#231;&#227;o e aprova&#231;&#227;o do autor da escala, a vers&#227;o traduzida foi testada em um grupo de vinte pacientes com hipertens&#227;o para verificar o entendimento das quest&#245;es de acordo com o seu significado original. As quest&#245;es foram entendidas identicamente por todos, e altera&#231;&#245;es subsequentes n&#227;o foram consideradas necess&#225;rias.</p>
    <fig id="quad1">
      <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gf01.jpg"/></fig>
    <p>A MMAS-8, atualiza&#231;&#227;o com maior sensibilidade da escala de quatro itens publicada em 1986 e considerada o m&#233;todo de autorrelato para determina&#231;&#227;o da ades&#227;o terap&#234;utica mais utilizado, contem oito perguntas com respostas fechadas de car&#225;ter dicot&#244;mico sim/n&#227;o, formuladas para evitar o vi&#233;s de respostas positivas dos pacientes a perguntas feitas por profissionais de sa&#250;de, por meio da invers&#227;o das respostas relacionadas ao comportamento aderente do entrevistado<sup>6,16</sup>. Desse modo, cada item mensurou um comportamento aderente espec&#237;fico, com sete perguntas que devem ser respondidas negativamente e apenas uma, positivamente, sendo a &#250;ltima quest&#227;o respondida segundo uma escala de cinco op&#231;&#245;es: nunca, quase nunca, &#224;s vezes, frequentemente, sempre. </p>
    <p>O grau de ades&#227;o terap&#234;utica foi determinado de acordo com a pontua&#231;&#227;o resultante da soma de todas as respostas corretas: alta ades&#227;o (oito pontos), m&#233;dia ades&#227;o (6 a &lt; 8 pontos) e baixa ades&#227;o (&lt; 6 pontos)<sup>17</sup>. No presente estudo, foram considerados aderentes aqueles pacientes com pontua&#231;&#227;o igual a oito na MMAS-8.</p>
    <p>Para avaliar a consist&#234;ncia interna do instrumento, utilizou-se a correla&#231;&#227;o item-total e o alfa de Cronbach.</p>
    <p>
      <bold>Tamanho da amostra</bold>
    </p>
    <p>Considerando o estudo original de Morisky e cols., no qual 16% dos pacientes obtiveram pontua&#231;&#227;o igual a 8 na MMAS-8, al&#233;m de precis&#227;o absoluta igual a 5% e intervalo de confian&#231;a de 95%, foi determinada uma amostra de 207 indiv&#237;duos. Com o prop&#243;sito de corrigir eventuais perdas e permitir uma melhor desagrega&#231;&#227;o das vari&#225;veis independentes, o tamanho amostral foi corrigido por um fator proporcional de 1,25. Desse modo, o tamanho da amostra para este estudo foi fixado em 230 pacientes. O n&#250;mero de pacientes necess&#225;rios para avaliar a consist&#234;ncia interna do instrumento foi consideravelmente menor, sendo obtido por meio da Abordagem N&#227;o Param&#233;trica para C&#225;lculo do Tamanho da Amostra com Base em Question&#225;rios ou Escalas de Avalia&#231;&#227;o na &#193;rea de Sa&#250;de, desenvolvido por Couto Jr.<sup>18</sup>, o qual estima o tamanho amostral por meio do n&#250;mero de itens e de categorias do instrumento de coleta.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>A an&#225;lise dos dados foi realizada por meio do programa SPSS vers&#227;o 12. As an&#225;lises estat&#237;sticas envolveram: an&#225;lises descritivas; teste de Kolmogorov-Smirnov para verificar o padr&#227;o de normalidade das vari&#225;veis cont&#237;nuas; qui-quadrado e Kruskal-Wallis para testar as rela&#231;&#245;es entre a ades&#227;o terap&#234;utica e outras vari&#225;veis independentes; e regress&#227;o log&#237;stica bin&#225;ria. Todas as vari&#225;veis com valor de p &lt; 0,25 na an&#225;lise bivariada foram inclu&#237;das no modelo inicial da an&#225;lise multivariada. Em seguida, foram retiradas, uma a uma, as vari&#225;veis que apresentaram maior valor de p, at&#233; que restassem apenas vari&#225;veis com signific&#226;ncia estat&#237;stica em pelo menos uma das categorias de ades&#227;o terap&#234;utica. Estabeleceu-se como n&#237;vel de signific&#226;ncia alfa menor que 5%. </p>
    <p>
      <bold>Aspectos &#233;ticos</bold>
    </p>
    <p>O trabalho foi aprovado pelo Comit&#234; de &#201;tica em Pesquisa da Universidade Federal de Alagoas em 6/11/2009, sob o n&#250;mero 010186/2009-01. Os dados foram coletados somente ap&#243;s a assinatura do termo de consentimento livre e esclarecido por todos os pacientes.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Foram selecionados 231 pacientes, oito dos quais declinaram a participa&#231;&#227;o no estudo (taxa de recusa = 3,5%). A idade m&#233;dia dos pacientes foi de 57,18 anos (&#177;12,7), com idade m&#237;nima de 27 e m&#225;xima de 85 anos, sendo a maioria (70,9%) do g&#234;nero feminino. Apenas 46 (20,6%) pacientes praticavam alguma atividade f&#237;sica regular. O tabagismo e o consumo de bebidas alco&#243;licas foram relatados por 10,3% e 18,8% dos pacientes, respectivamente. Nenhuma das vari&#225;veis investigadas apresentou associa&#231;&#227;o com a ades&#227;o terap&#234;utica ou com o controle da press&#227;o arterial (<xref ref-type="table" rid="aop05012tab01m">tabela 1</xref> e <xref ref-type="table" rid="aop05012tab02m">2</xref>). </p>
    <p content-type="asset">
      <table-wrap id="aop05012tab01m">
        <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gt01.jpg"/></table-wrap>
    </p>
    <p content-type="asset">
      <table-wrap id="aop05012tab02m">
        <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gt02.jpg"/></table-wrap>
    </p>
    <p>
      <bold>Ades&#227;o terap&#234;utica e controle da press&#227;o arterial</bold>
    </p>
    <p>Apenas 34,1% dos pacientes apresentaram valores de press&#227;o arterial sob controle. A taxa de ades&#227;o terap&#234;utica (MMAS-8 = 8, alta ades&#227;o) foi de 19,7%. O valor m&#233;dio de ades&#227;o segundo a MMAS-8 foi 5,8 (&#177;1,8). Entre os pacientes considerados n&#227;o aderentes, 33,2% apresentaram ades&#227;o m&#233;dia, e 47,1%, baixa ades&#227;o terap&#234;utica. De acordo com a an&#225;lise de regress&#227;o log&#237;stica, os pacientes que atingiram valores m&#225;ximos na MMAS-8 se revelaram mais propensos (OR = 6,1; IC [95%] = 3,0 a 12,0) a ter a press&#227;o arterial sob controle do que aqueles que atingiram valores m&#233;dios (6 a &lt; 8) ou baixos (&lt; 6). A associa&#231;&#227;o do controle da PA (p = 0,000) e das m&#233;dias de PAS e PAD (p = 0,002510 e p = 0,000135, respectivamente) com o grau de ades&#227;o terap&#234;utica pode ser observada na <xref ref-type="table" rid="aop05012tab03m">tabela 3</xref>.</p>
    <p content-type="asset">
      <table-wrap id="aop05012tab03m">
        <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gt03.jpg"/></table-wrap>
    </p>
    <p>Em adi&#231;&#227;o, essas associa&#231;&#245;es podem ser empregadas para investigar a suspeita de uma ades&#227;o terap&#234;utica aqu&#233;m do ideal naqueles pacientes com PA n&#227;o controlada: 75,6% dos pacientes com PA n&#227;o controlada n&#227;o aderiram ao tratamento anti-hipertensivo, enquanto 33,3% dos pacientes com PA sob controle eram n&#227;o aderentes.</p>
    <p>
      <bold>Uso de medicamentos</bold>
    </p>
    <p>A m&#233;dia de medicamentos prescritos por paciente foi de 3,15 (&#177;1,63; 3,11 entre os aderentes, e 3,16 entre os n&#227;o aderentes) e a m&#233;dia de anti-hipertensivos foi de 1,61 por paciente (&#177;0,65; 1,51 entre os aderentes e 1,67 entre os n&#227;o aderentes). Os medicamentos mais prescritos foram: hidroclorotiazida (para 53,3% dos pacientes), captopril (49,9%), propranolol (14,3%), enalapril (12,1%), anlodipino (11,2%), atenolol (8,5%) e losartan (4,9%). A maioria dos pacientes (52,5%) fazia uso da mesma farmacoterapia anti-hipertensiva h&#225; cinco anos ou mais; 20,2% usavam o mesmo tratamento h&#225; tr&#234;s ou quatro anos; 12,6% usavam de um a dois anos; 8,5%, de seis meses a um ano; e 6,3%, h&#225; menos de seis meses.</p>
    <p>A monoterapia anti-hipertensiva foi prescrita para 47,1% dos pacientes, 45,3% estavam em uso de dois f&#225;rmacos anti-hipertensivos e 7,1% estavam usando tr&#234;s ou mais f&#225;rmacos, um dos quais diur&#233;tico. Enquanto 36,2% dos pacientes sob monoterapia e 36,6% dos pacientes em uso de dois medicamentos estavam com a press&#227;o arterial controlada (<xref ref-type="table" rid="aop05012tab02m">tab. 2</xref>), apenas 5,9% dos pacientes em uso de tr&#234;s ou mais anti-hipertensivos apresentaram o mesmo desfecho (p = 0,038).</p>
    <p>Entre os pacientes com press&#227;o arterial n&#227;o controlada, 2,7% (1,8% do total de pacientes) eram ao mesmo tempo aderentes e usu&#225;rios de tr&#237;plice terapia anti-hipertensiva contendo um diur&#233;tico, caracterizando a hipertens&#227;o resistente. Os outros pacientes que apresentaram valores de PA elevados se dividiram da seguinte maneira: 8,2% n&#227;o aderiram &#224; terapia tr&#237;plice com um diur&#233;tico; 8,8% eram aderentes, mas faziam uso de um ou dois anti-hipertensivos; e 80,3% n&#227;o eram aderentes e fazia uso de um ou dois anti-hipertensivos (<xref ref-type="table" rid="aop05012tab04m">tab. 4</xref>).</p>
    <p content-type="asset">
      <table-wrap id="aop05012tab04m">
        <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gt04.jpg"/></table-wrap>
    </p>
    <p>
      <bold>Confiabilidade da escala</bold>
    </p>
    <p>A correla&#231;&#227;o item-total corrigida resultou em um valor inferior a 0,20 para o item 3, considerado baixo, embora significantemente diferente de zero. Por&#233;m, os valores do alfa de Cronbach resultante da exclus&#227;o de cada item foram inferiores, sem exce&#231;&#227;o, ao coeficiente resultante (&#945; = 0,69), indicando que a inclus&#227;o do item 3 n&#227;o prejudica a confiabilidade do instrumento (<xref ref-type="table" rid="aop05012tab05m">tab. 5</xref>).</p>
    <p content-type="asset">
      <table-wrap id="aop05012tab05m">
        <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gt05.jpg"/></table-wrap>
    </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>As Doen&#231;as Cardiovasculares (DCV), cujo principal fator de risco &#233; a hipertens&#227;o<sup>19,20</sup>, s&#227;o a maior causa da mortalidade em todo o mundo e no Brasil, onde foram respons&#225;veis por 32% dos &#243;bitos de indiv&#237;duos acima de trinta anos em 2005<sup>21</sup>. Diversas medidas de controle da PA v&#234;m sendo testadas<sup>22,23</sup>; contudo, nem mesmo as fortes evid&#234;ncias de que v&#225;rios tratamentos medicamentosos anti-hipertensivos s&#227;o efetivos na redu&#231;&#227;o da morbidade e da mortalidade cardiovascular significam percentuais de controle de Press&#227;o Arterial (PA) adequados, em virtude da baixa ades&#227;o ao tratamento<sup>9,24</sup>. Estudos com a popula&#231;&#227;o brasileira indicam um controle de PA de 20% a 60%<sup>20</sup><sup>,25-27</sup>, margem dentro da qual se encontra a taxa de controle da PA observada em nosso estudo.</p>
    <p>De acordo com a literatura, a baixa ades&#227;o prejudica a evolu&#231;&#227;o cl&#237;nica do paciente e sua qualidade de vida, causando desfechos adversos, tais como o aumento da morbimortalidade e dos gastos em sa&#250;de<sup>28</sup>. No tratamento da hipertens&#227;o, sua primeira consequ&#234;ncia &#233; a falha no controle da PA; v&#225;rios estudos ressaltam essa rela&#231;&#227;o, encontrada tamb&#233;m em nossa investiga&#231;&#227;o, na qual valores significativamente menores de press&#227;o arterial sist&#243;lica e diast&#243;lica foram observados entre os pacientes com alto grau de ades&#227;o<sup>6,29,30</sup>.</p>
    <p>A categoriza&#231;&#227;o dicot&#244;mica da ades&#227;o terap&#234;utica em pacientes aderentes vs pacientes n&#227;o aderentes foi baseada, a exemplo do estudo original, na rela&#231;&#227;o da escala com o controle da press&#227;o arterial. No entanto, no presente estudo, foram considerados aderentes apenas aqueles pacientes com alto grau de ades&#227;o (pontua&#231;&#227;o igual a 8), uma vez que esse grupo apresentou rela&#231;&#227;o com o controle da press&#227;o arterial (<xref ref-type="table" rid="aop05012tab03m">tab. 3</xref>). J&#225; no estudo de Morisky e cols.<sup>6</sup> foram considerados aderentes os pacientes com alta e m&#233;dia ades&#227;o.</p>
    <p>Embora os protocolos de aplica&#231;&#227;o sejam id&#234;nticos, os resultados sugerem que a interpreta&#231;&#227;o da pontua&#231;&#227;o seja diferente, tornando alvo de cuidados centrados na melhoria do comportamento aderente n&#227;o apenas os pacientes com baixo grau de ades&#227;o, mas tamb&#233;m aqueles com grau m&#233;dio. Em nosso estudo, 65,1% dos pacientes com alta ades&#227;o e 37,0% dos pacientes com grau m&#233;dio de ades&#227;o tinham a PA sob controle, enquanto no estudo original a diferen&#231;a entre ambos grupos foi menor (56,7% e 44,8%, respectivamente). Em contrapartida, os dois estudos observaram uma baixa taxa de pacientes com alto grau de ades&#227;o, inferior a 20%.</p>
    <p>Inicialmente, o uso da primeira escala de ades&#227;o terap&#234;utica de Morisky (MMAS-4) permitia n&#227;o apenas determinar aqueles pacientes n&#227;o aderentes em risco de n&#227;o atingir o controle da PA, como tamb&#233;m conhecer algumas causas da ades&#227;o insatisfat&#243;ria. &#192; medida que novos m&#233;todos de autorrelato foram desenvolvidos, a utilidade como instrumento de triagem na pr&#225;tica cl&#237;nica se tornou uma caracter&#237;stica cada vez mais desej&#225;vel. No atendimento de pacientes com hipertens&#227;o n&#227;o controlada, por exemplo, a investiga&#231;&#227;o das causas prov&#225;veis deve considerar sempre que poss&#237;vel a n&#227;o ades&#227;o. Em nosso estudo, a vers&#227;o traduzida da MMAS-8 identificou uma grande propor&#231;&#227;o de n&#227;o aderentes entre os pacientes com press&#227;o arterial n&#227;o controlada, mais que o dobro da propor&#231;&#227;o de n&#227;o aderentes entre os pacientes com PA sob controle.</p>
    <p>Segundo a Organiza&#231;&#227;o Mundial de Sa&#250;de, 51% dos pacientes com hipertens&#227;o arterial nos Estados Unidos aderem ao tratamento, enquanto na China a taxa de ades&#227;o terap&#234;utica entre esses pacientes &#233; de 43%<sup>3</sup>. Hyre e cols.<sup>29</sup>, em estudo com a MMAS-8 aplicada a pacientes portadores de hipertens&#227;o, observaram que 35,6% dos pacientes aderiram integralmente &#224; prescri&#231;&#227;o. Contudo, em tais estudos, o custo dos medicamentos era um fator que dificultava a ades&#227;o dos pacientes, enquanto os pacientes inclu&#237;dos no presente estudo tinham acesso gratuito aos tratamentos anti-hipertensivos. O custo dos medicamentos &#233; o fator preditivo da n&#227;o ades&#227;o mais amplamente estudado<sup>8,31</sup>, e sua import&#226;ncia no cumprimento dos tratamentos anti-hipertensivos tem sido demonstrada em estudos envolvendo grande n&#250;mero de pacientes<sup>32,33</sup>. Apesar disso, a taxa de aderentes observada na atual investiga&#231;&#227;o foi menor que nos estudos acima, indicando que o acesso gratuito aos tratamentos anti-hipertensivos per se n&#227;o implicou n&#237;veis satisfat&#243;rios de ades&#227;o.</p>
    <p>De acordo com dois dos principais estudos de revis&#227;o sobre a ades&#227;o terap&#234;utica, um dos quais abrangendo cinquenta anos de pesquisa sobre o tema, a ades&#227;o n&#227;o tem rela&#231;&#227;o aparente com caracter&#237;sticas demogr&#225;ficas - como g&#234;nero, idade, n&#237;vel socioecon&#244;mico e grupo &#233;tnico - e gravidade da doen&#231;a<sup>2,31</sup>. Alguns preditores, no entanto, t&#234;m sido consistentemente associados com a baixa ades&#227;o, dentre os quais se destacam a complexidade do esquema terap&#234;utico, o tratamento de doen&#231;as assintom&#225;ticas, a presen&#231;a de problemas psicol&#243;gicos como a depress&#227;o e os efeitos colaterais dos medicamentos<sup>34</sup>. &#192; exce&#231;&#227;o dos problemas psicol&#243;gicos, que n&#227;o foram considerados em nosso estudo, os demais fatores tiveram pouca ou nenhuma influ&#234;ncia sobre o comportamento aderente dos pacientes estudados. A complexidade do esquema terap&#234;utico tem no n&#250;mero de medicamentos prescritos o seu componente mais relevante<sup>34</sup>. Contudo, n&#227;o foi observada associa&#231;&#227;o entre o n&#250;mero de medicamentos utilizados, assim como sua posologia, e a ades&#227;o terap&#234;utica. </p>
    <p>Quanto aos preditores do controle da PA, recentemente, o estudo ALLHAT<sup>35</sup> - um ensaio cl&#237;nico randomizado envolvendo um grande n&#250;mero de pacientes destinado a examinar o controle da hipertens&#227;o e os efeitos dos anti-hipertensivos sobre desfechos cl&#237;nicos - identificou n&#237;veis basais elevados de PA, etnia negra e idade como os maiores preditores da falta de controle da PA. Entre as causas adicionais, destacam-se g&#234;nero feminino, diagn&#243;stico de diabetes, obesidade, terapia anti-hipertensiva pr&#233;via e hipertrofia ventricular esquerda<sup>35</sup>. Dentre todos esses fatores, apenas idade, g&#234;nero, uso de hipoglicemiantes orais e tempo de tratamento anti-hipertensivo foram considerados na presente investiga&#231;&#227;o. Ainda assim, a &#250;nica vari&#225;vel associada &#224; falta de controle da press&#227;o arterial, al&#233;m da n&#227;o ades&#227;o, foi a utiliza&#231;&#227;o de tr&#234;s ou mais anti-hipertensivos.</p>
    <p>Uma hip&#243;tese para esse achado &#233; que, mesmo entre pacientes considerados aderentes pela MMAS-8, pode haver uma utiliza&#231;&#227;o incorreta dos medicamentos. A escala de ades&#227;o traduzida e validada para este estudo, embora contenha v&#225;rias quest&#245;es relacionadas a comportamentos n&#227;o aderentes espec&#237;ficos, n&#227;o aborda quest&#245;es como hor&#225;rio e modo de usar, o que pode explicar a aus&#234;ncia de associa&#231;&#227;o entre o uso de tr&#234;s ou mais anti-hipertensivos com uma ades&#227;o inadequada, mas a exist&#234;ncia de associa&#231;&#227;o entre o n&#250;mero desses medicamentos e o n&#227;o controle da PA. Outra hip&#243;tese &#233; o maior grau de severidade da condi&#231;&#227;o cl&#237;nica desses pacientes, implicando uma maior dificuldade de controlar a PA. Ademais, fatores importantes como a qualidade da farmacoterapia praticada no &#226;mbito do Sistema &#218;nico de Sa&#250;de devem ser investigados para a precisa identifica&#231;&#227;o de causas relevantes da hipertens&#227;o n&#227;o controlada. </p>
    <p>Na pr&#225;tica cl&#237;nica, pacientes aderentes ao tratamento e n&#227;o responsivos &#224; tr&#237;plice terapia anti-hipertensiva otimizada que inclua um diur&#233;tico caracterizam a situa&#231;&#227;o de hipertens&#227;o resistente<sup>9-11</sup>. De acordo com esse conceito, 1,8% dos pacientes entrevistados apresentou hipertens&#227;o resistente. A preval&#234;ncia da hipertens&#227;o resistente, que em geral &#233; desconhecida, foi recentemente estimada nos Estados Unidos da Am&#233;rica, correspondendo a aproximadamente 8,9% dos pacientes hipertensos<sup>36</sup>. Nessa situa&#231;&#227;o &#233; necess&#225;rio avaliar a presen&#231;a de fatores que dificultam o controle da press&#227;o arterial, tais como ingest&#227;o excessiva de s&#243;dio, &#225;lcool, obesidade, uso de f&#225;rmacos com potencial de elevar a press&#227;o arterial, s&#237;ndrome de apneia obstrutiva do sono e formas secund&#225;rias de hipertens&#227;o arterial, procedendo-se a corre&#231;&#227;o desses fatores<sup>9</sup>.</p>
    <p>Por sua vez, o termo "hipertens&#227;o pseudorresistente" se refere &#224; falta de controle da PA em um paciente com tratamento apropriado exposto a outros fatores que contribuem para elevar a leitura da PA, tais como t&#233;cnica de medida inapropriada, efeito do jaleco branco e baixa ades&#227;o<sup>10,11</sup>. A escolha do(s) f&#225;rmaco(s) ou da(s) dose(s), a primeira das causas da hipertens&#227;o pseudorresistente, n&#227;o foi analisada individualmente em nosso estudo, e sim considerada de acordo com os anti-hipertensivos e faixas de dosagem contidos na Rela&#231;&#227;o Nacional de Medicamentos Essenciais (Rename)<sup>37</sup>. Portanto, nenhuma escolha terap&#234;utica foi considerada inapropriada. Desse modo, todos os pacientes com PA n&#227;o controlada que n&#227;o tinham hipertens&#227;o resistente foram classificados como portadores de hipertens&#227;o do tipo pseudorresistente: 64,1% dos pacientes apresentaram esse tipo de hipertens&#227;o. A hipertens&#227;o pseudorresistente causada por baixa ades&#227;o correspondeu a 58,3% do total de pacientes inclu&#237;dos no estudo. &#201; relevante considerar que esse valor poderia ser ainda maior, uma vez que os m&#233;todos de autorrelato t&#234;m como limita&#231;&#227;o principal a subestima&#231;&#227;o do n&#250;mero de n&#227;o aderentes. </p>
    <p>Por sua vez, os m&#233;todos de autorrelato para determina&#231;&#227;o da ades&#227;o terap&#234;utica, em contraste com t&#233;cnicas como a quantifica&#231;&#227;o de f&#225;rmacos e seus metab&#243;litos em fluidos org&#226;nicos, o monitoramento eletr&#244;nico da medica&#231;&#227;o (Medication Event Monitoring System - MEMS) ou a contagem de comprimidos n&#227;o utilizados pelo paciente, s&#227;o simples, r&#225;pidos, n&#227;o invasivos e econ&#244;micos, e podem proporcionar um parecer em tempo real a respeito do comportamento aderente do paciente e as raz&#245;es potenciais para a n&#227;o ades&#227;o<sup>38</sup>. Embora tais m&#233;todos estejam sujeitos a vieses, como a superestima&#231;&#227;o da ades&#227;o, o constante aprimoramento desses instrumentos e estudos sobre suas valida&#231;&#245;es em diferentes popula&#231;&#245;es t&#234;m aumentado sua ado&#231;&#227;o na pr&#225;tica cl&#237;nica<sup>6</sup>.</p>
    <p>A consist&#234;ncia interna do instrumento, medida pelo alfa de Cronbach (0,69), foi inferior &#224;quela obtida por Morisky e cols.<sup>6</sup> em pacientes com hipertens&#227;o (0,83); por&#233;m, um pouco superior aos valores de consist&#234;ncia interna observados nos estudos de tradu&#231;&#227;o da escala para outros idiomas publicados at&#233; o momento<sup>39</sup>. De acordo com A&#241;ez e cols.<sup>40</sup>, um valor de alfa maior do que 0,5 tem sido considerado aceit&#225;vel em estudos de valida&#231;&#227;o de question&#225;rios, valor que foi adotado por Al-Qazaz em estudo de adapta&#231;&#227;o transcultural da MMAS-8 para o idioma malaio<sup>39</sup>. Embora algumas quest&#245;es tenham apresentado menor correla&#231;&#227;o item-total, como &#233; o caso das quest&#245;es 3, 4 e 7, observou-se que a elimina&#231;&#227;o de tais quest&#245;es n&#227;o aumentaria o alfa do instrumento, o que tornaria injustific&#225;vel sua exclus&#227;o, uma vez que isso descaracterizaria o instrumento.</p>
    <p>No presente estudo, o MMAS-8 apresentou um potencial satisfat&#243;rio como instrumento de triagem na pr&#225;tica cl&#237;nica para a identifica&#231;&#227;o de pacientes n&#227;o aderentes e em risco de descontrole da PA, considerando-se a confiabilidade da vers&#227;o traduzida, sua rela&#231;&#227;o de signific&#226;ncia com o controle da PA e com os valores de PAS e PAD, sua simplicidade e valida&#231;&#227;o em outros estudos com pacientes hipertensos. No &#226;mbito do SUS, essa escala pode ser uma ferramenta importante no controle da hipertens&#227;o. Outra investiga&#231;&#227;o mais ampla para determina&#231;&#227;o da ades&#227;o terap&#234;utica em pacientes sob uso de anti-hipertensivos de acesso gratuito vem sendo conduzida.</p>
    <p>
      <bold>Limita&#231;&#245;es</bold>
    </p>
    <p>Neste estudo alguns preditores da n&#227;o ades&#227;o - tais como depress&#227;o - e do n&#227;o controle da press&#227;o arterial - tais como etnia e n&#237;veis basais elevados de press&#227;o arterial sist&#243;lica e diast&#243;lica - n&#227;o foram investigados como vari&#225;veis de interesse ou mesmo considerados no processo de inclus&#227;o dos pacientes. A classifica&#231;&#227;o dos pacientes com hipertens&#227;o n&#227;o controlada segundo o tipo hipertens&#227;o pseudorresistente tamb&#233;m est&#225; sujeita a vi&#233;s de interpreta&#231;&#227;o, uma vez que apesar da atenta observa&#231;&#227;o de outros fatores causais da hipertens&#227;o pseudorresistente, e dos esfor&#231;os para redu&#231;&#227;o ou controle de alguns deles, tais como o efeito do jaleco branco e inadequada medida da press&#227;o arterial, a &#250;nica causa que pode ser determinada com precis&#227;o foi a ades&#227;o terap&#234;utica.</p>
    <p>
      <bold>Considera&#231;&#245;es finais</bold>
    </p>
    <p>O diagn&#243;stico do comportamento n&#227;o aderente por meio da aplica&#231;&#227;o da nova Escala de Ades&#227;o Terap&#234;utica de Morisky de oito itens em pacientes sob uso de medicamentos anti-hipertensivos foi um fator preditivo de valores elevados de press&#227;o arterial sist&#243;lica e diast&#243;lica. Considerando-se que a n&#227;o ades&#227;o &#233; uma das principais causas da press&#227;o arterial n&#227;o controlada, o uso de escalas de autorrelato relacionadas com a PA &#233; uma medida simples e de baixo custo para auxiliar o atendimento cl&#237;nico de pacientes com hipertens&#227;o.</p>
    <p>
      <bold>Agradecimentos</bold>
    </p>
    <p>Agradecemos o apoio da Secretaria Municipal de Sa&#250;de de Macei&#243;; das equipes multidisciplinares das Unidades de Sa&#250;de da Fam&#237;lia; a Equipe do Programa de Educa&#231;&#227;o Tutorial em Sa&#250;de (PET-Sa&#250;de) da UFAL; Dr. Donald E. Morisky, da University of California, Los Angeles (Ucla). Al&#233;m do cuidadoso trabalho de coleta de dados sob a responsabilidade dos farmac&#234;uticos Cl&#225;udia C. N&#243;brega de Farias Ayres, Fernanda Bertazolli Albieri, Hugo A. Leite Mota Vasconcelos, Mirela Quirino de Almeida, Morgana R. Maciel Cabral Davino, Natyelle M. Santos Macedo e todos os pacientes que participaram deste estudo.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi financiado parcialmente por Funda&#231;&#227;o de Apoio &#224; Pessoa do Estado de Alagoas (FAPEAL) </p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte da tese de doutorado de Alfredo Dias de Oliveira Filho (N&#250;cleo de P&#243;s-gradua&#231;&#227;o em Medicina - UFS) pela Universidade Federal de Sergipe e Universidade Federal de Alagoas.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold> Correspond&#234;ncia:</bold>
        </label>
        <p> Divaldo Pereira de Lyra Junior </p>
        <p> Cidade Universit&#225;ria Prof. "Jos&#233; Alo&#237;sio de Campos" </p>
        <p> Av. Marechal Rondon, s/n Jardim Rosa Elza </p>
        <p> CEP 49100-000, S&#227;o Cristov&#227;o, SE - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="lepfs.ufs@gmail.com">lepfs.ufs@gmail.com</email>, </p>
        <p>
          <email xlink:href="lyra_jr@hotmail.com">lyra_jr@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 28/07/11, revisado em 11/08/11; aceito em 17/01/12.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed. 2007;9(3):58.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Medication nonadherence: an unrecognized cardiovascular risk factor</article-title>
          <source>MedGenMed</source>
          <date>
            <year>2007</year>
          </date>
          <issue>3</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Munger</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Van Tassell</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>LaFleur</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research</article-title>
          <source>Med Care</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>200</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>DiMatteo</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. World Health Organization (WHO). Adherence to long-term therapies: evidence for action. Geneva( Switzerland); 2003.</mixed-citation>
        <element-citation publication-type="book">
          <source>Adherence to long-term therapies: evidence for action</source>
          <date>
            <year>2003</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Carneiro Junior N, de Jesus CH, Crevelim MA. A Estrat&#233;gia Sa&#250;de da Fam&#237;lia para a equidade de acesso dirigida &#224; popula&#231;&#227;o em situa&#231;&#227;o de rua em grandes centros urbanos. Saude Soc S&#227;o Paulo. 2010;19(3):709-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A Estrat&#233;gia Sa&#250;de da Fam&#237;lia para a equidade de acesso dirigida &#224; popula&#231;&#227;o em situa&#231;&#227;o de rua em grandes centros urbanos</article-title>
          <source>Saude Soc S&#227;o Paulo</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>709</fpage>
          <lpage>16</lpage>
          <issue>3</issue>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carneiro Junior</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>de Jesus</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Crevelim</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Concurrent and predictive validity of a self-reported measure of medication adherence</article-title>
          <source>Med Care</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>67</fpage>
          <lpage>74</lpage>
          <issue>1</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morisky</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictive validity of a medication adherence measure in an outpatient setting</article-title>
          <source>J Clin Hypertens (Greenwich)</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>348</fpage>
          <lpage>54</lpage>
          <issue>5</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morisky</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Ang</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Krousel-Wood</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Obreli-Neto PR, Prado MF, Vieira JC, Fachini FC, Pelloso SM, Marcon SS, et al. Fatores interferentes na taxa de ades&#227;o &#224; farmacoterapia em idosos atendidos na rede p&#250;blica de sa&#250;de do Munic&#237;pio de Salto Grande - SP, Brasil. Rev Cienc Farm Basica Apl. 2010;31(3):229-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Fatores interferentes na taxa de ades&#227;o &#224; farmacoterapia em idosos atendidos na rede p&#250;blica de sa&#250;de do Munic&#237;pio de Salto Grande - SP, Brasil</article-title>
          <source>Rev Cienc Farm Basica Apl</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>229</fpage>
          <lpage>33</lpage>
          <issue>3</issue>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Obreli-Neto</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Prado</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Vieira</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Fachini</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Pelloso</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Marcon</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Piette JD, Rosland AM, Silveira MJ, Hayward R, McHorney CA. Medication cost problems among chronically ill adults in the US: did the financial crisis make a bad situation even worse? Patient Prefer Adherence. 2011;5:187-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Medication cost problems among chronically ill adults in the US: did the financial crisis make a bad situation even worse?</article-title>
          <source>Patient Prefer Adherence</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>187</fpage>
          <lpage>94</lpage>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Piette</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Rosland</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Silveira</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Hayward</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>McHorney</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Sociedade Brasileira de Cardiologia / Sociedade Brasileira de Hipertens&#227;o / Sociedade Brasileira de Nefrologia. VI Diretrizes Brasileiras de Hipertens&#227;o. Arq Bras Cardiol. 2010;95(1 supl.1):1-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>VI Diretrizes Brasileiras de Hipertens&#227;o</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>1</fpage>
          <lpage>51</lpage>
          <issue>1</issue>
          <volume>95</volume>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Arq Bras Cardiol. 2007;88(6):683-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mechanisms and treatment of resistant hypertension</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>683</fpage>
          <lpage>92</lpage>
          <issue>6</issue>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pimenta</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Calhoun</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Oparil</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52(22):1749-57.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Resistant hypertension: an overview of evaluation and treatment</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1749</fpage>
          <lpage>57</lpage>
          <issue>22</issue>
          <volume>52</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sarafidis</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Bakris</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Spence JD. White-coat hypertension is hypertension. Hypertension. 2008;51(5):1272.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>White-coat hypertension is hypertension</article-title>
          <source>Hypertension</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1272</fpage>
          <issue>5</issue>
          <volume>51</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Spence</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14(12):1263-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Is resistant hypertension really resistant</article-title>
          <source>Am J Hypertens</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1263</fpage>
          <lpage>9</lpage>
          <issue>12</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Buddle</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Beaton D, Bombardier C, Guillemin F, Ferraz MB. Recommendations for the cross-cultural adaptation of health status measures. Rosemont(Illinois): American Academy of Osthopaedic Surgeons/Institute for Work &amp;Health; 2002.</mixed-citation>
        <element-citation publication-type="book">
          <source>Recommendations for the cross-cultural adaptation of health status measures</source>
          <date>
            <year>2002</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Beaton</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bombardier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Guillemin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ferraz</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005;8(2):94-104.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ISPOR Task Force for Translation and Cultural Adaptation: Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation</article-title>
          <source>Value Health</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>94</fpage>
          <lpage>104</lpage>
          <issue>2</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wild</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Grove</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eremenco</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McElroy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Verjee-Lorenz</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Voils CI, Hoyle RH, Thorpe CT, Maciejewski ML, Yancy WS Jr. Improving the measurement of self-reported medication nonadherence. J Clin Epidemiol. 2011;64(3):250-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Improving the measurement of self-reported medication nonadherence</article-title>
          <source>J Clin Epidemiol</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>250</fpage>
          <lpage>4</lpage>
          <issue>3</issue>
          <volume>64</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Voils</surname>
              <given-names>CI</given-names>
            </name>
            <name>
              <surname>Hoyle</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Thorpe</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Maciejewski</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Yancy Jr</surname>
              <given-names>WS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15(1):59-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New medication adherence scale versus pharmacy fill rates in seniors with hypertension</article-title>
          <source>Am J Manag Care</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>59</fpage>
          <lpage>66</lpage>
          <issue>1</issue>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Krousel-Wood</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Islam</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Webber</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Re</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Morisky</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Muntner</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Couto Jr EB. Abordagem n&#227;o-param&#233;trica para c&#225;lculo do tamanho de amostra com base em question&#225;rios ou escalas de avalia&#231;&#227;o na &#225;rea de sa&#250;de [tese]. S&#227;o Paulo: Universidade de S&#227;o Paulo; 2009.</mixed-citation>
        <element-citation publication-type="thesis">
          <source>Abordagem n&#227;o-param&#233;trica para c&#225;lculo do tamanho de amostra com base em question&#225;rios ou escalas de avalia&#231;&#227;o na &#225;rea de sa&#250;de</source>
          <date>
            <year>2009</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Couto Jr</surname>
              <given-names>EB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Cesarino CB, Cipullo JP, Martin JF, Ciorlia LA, Godoy MR, Cordeiro JA, et al. Preval&#234;ncia e fatores sociodemogr&#225;ficos em hipertensos de S&#227;o Jos&#233; do Rio Preto. Arq Bras Cardiol. 2008;91(1):29-35.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Preval&#234;ncia e fatores sociodemogr&#225;ficos em hipertensos de S&#227;o Jos&#233; do Rio Preto</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>29</fpage>
          <lpage>35</lpage>
          <issue>1</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cesarino</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Cipullo</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Ciorlia</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Godoy</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Cordeiro</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Ros&#225;rio TM, Scala LC, Fran&#231;a GV, Pereira MR, Jardim PC. Preval&#234;ncia, controle e tratamento da hipertens&#227;o arterial sist&#234;mica em Nobres, MT. Arq Bras Cardiol. 2009;93(6):672-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Preval&#234;ncia, controle e tratamento da hipertens&#227;o arterial sist&#234;mica em Nobres, MT</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>672</fpage>
          <lpage>8</lpage>
          <issue>6</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ros&#225;rio</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Scala</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Fran&#231;a</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Jardim</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Taylor J. Cardiology in Brazil: a country in development. Eur Heart J. 2010;31(13):1541-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiology in Brazil: a country in development</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>1541</fpage>
          <lpage>2</lpage>
          <issue>13</issue>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Curioni C, Cunha CB, Veras RP, Andr&#233; C. The decline in mortality from circulatory diseases in Brazil. Rev Panam Salud Publica. 2009;25(1):9-15.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The decline in mortality from circulatory diseases in Brazil</article-title>
          <source>Rev Panam Salud Publica</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>9</fpage>
          <lpage>15</lpage>
          <issue>1</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Curioni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cunha</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Veras</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Andr&#233;</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Cesse EAP, Carvalho EF, Souza WV, Luna CF. Tend&#234;ncia da mortalidade por doen&#231;as do aparelho circulat&#243;rio no Brasil: 1950 a 2000. Arq Bras Cardiol. 2009;93(5):490-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tend&#234;ncia da mortalidade por doen&#231;as do aparelho circulat&#243;rio no Brasil: 1950 a 2000</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>490</fpage>
          <lpage>7</lpage>
          <issue>5</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cesse</surname>
              <given-names>EAP</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>WV</given-names>
            </name>
            <name>
              <surname>Luna</surname>
              <given-names>CF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD001841.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>First-line drugs for hypertension</article-title>
          <source>Cochrane Database Syst Rev</source>
          <date>
            <year>2009</year>
            <day>08</day>
            <month>07</month>
          </date>
          <fpage>CD001841</fpage>
          <issue>3</issue>
          <person-group person-group-type="author">
            <name>
              <surname>Wright</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Musini</surname>
              <given-names>VM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Strelec MA, Pierin AM, Mion D Jr. A influ&#234;ncia do conhecimento sobre a doen&#231;as e atitude frente a tomada dos rem&#233;dios no controle da hipertens&#227;o arterial. Arq Bras Cardiol. 2003;81(4):349-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A influ&#234;ncia do conhecimento sobre a doen&#231;as e atitude frente a tomada dos rem&#233;dios no controle da hipertens&#227;o arterial</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>349</fpage>
          <lpage>54</lpage>
          <issue>4</issue>
          <volume>81</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Strelec</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Pierin</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Mion Jr</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Moreira GC, Cipullo JP, Martin JF, Ciorlia LA, Godoy MR, Cesarino CB, et al. Evaluation of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study. J Hypertens. 2009;27(9):1900-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study</article-title>
          <source>J Hypertens</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1900</fpage>
          <lpage>7</lpage>
          <issue>9</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moreira</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Cipullo</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Ciorlia</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Godoy</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Cesarino</surname>
              <given-names>CB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Nogueira D, Faerstein E, Coeli CM, Chor D, Lopes C de S, Werneck GL. [Awareness, treatment, and control of arterial hypertension: Pr&#243;-Sa&#250;de study, Brazil]. Rev Panam Salud Publica. 2010;27(2):103-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>[Awareness, treatment, and control of arterial hypertension: Pr&#243;-Sa&#250;de study, Brazil]</article-title>
          <source>Rev Panam Salud Publica</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>103</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nogueira</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Faerstein</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Coeli</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Chor</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>C de S</given-names>
            </name>
            <name>
              <surname>Werneck</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16(8):568-76.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Antihypertensive medication adherence and subsequent healthcare utilization and costs</article-title>
          <source>Am J Manag Care</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>568</fpage>
          <lpage>76</lpage>
          <issue>8</issue>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pittman</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Stettin</surname>
              <given-names>GD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Hyre AD, Krousel-Wood MA, Muntner P, Kawasaki L, DeSalvo KB. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens (Greenwich). 2007;9(3):179-86.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting</article-title>
          <source>J Clin Hypertens (Greenwich)</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>179</fpage>
          <lpage>86</lpage>
          <issue>3</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hyre</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Krousel-Wood</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Muntner</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kawasaki</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>DeSalvo</surname>
              <given-names>KB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Morgado M, Rolo S, Macedo AF, Pereira L, Castelo-Branco M. Predictors of uncontrolled hypertension and antihypertensive medication nonadherence. J Cardiovasc Dis Res. 2010;1(4):196-202.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictors of uncontrolled hypertension and antihypertensive medication nonadherence</article-title>
          <source>J Cardiovasc Dis Res</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>196</fpage>
          <lpage>202</lpage>
          <issue>4</issue>
          <volume>1</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morgado</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rolo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Macedo</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Castelo-Branco</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Adherence to medication</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>487</fpage>
          <lpage>97</lpage>
          <issue>5</issue>
          <volume>353</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Osterberg</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Blaschke</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12(11):678-83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care</article-title>
          <source>Am J Manag Care</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>678</fpage>
          <lpage>83</lpage>
          <issue>11</issue>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Taira</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Frech-Tamas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Maciejewski ML, Bryson CL, Perkins M, Blough DK, Cunningham FE, Fortney JC, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manag Care. 2010;16(1):e20-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications</article-title>
          <source>Am J Manag Care</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>e20</fpage>
          <lpage>34</lpage>
          <issue>1</issue>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Maciejewski</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Bryson</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Perkins</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Blough</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Cunningham</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Fortney</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. George J, Phun YT, Bailey MJ, Kong DC, Stewart K. Development and validation of the medication regimen complexity index. Ann Pharmacother. 2004;38(9):1369-76.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Development and validation of the medication regimen complexity index</article-title>
          <source>Ann Pharmacother</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1369</fpage>
          <lpage>76</lpage>
          <issue>9</issue>
          <volume>38</volume>
          <person-group person-group-type="author">
            <name>
              <surname>George</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Phun</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)</article-title>
          <source>J Clin Hypertens (Greenwich)</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>393</fpage>
          <lpage>404</lpage>
          <issue>6</issue>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cushman</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Cutler</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Margolis</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Grimm</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of resistant hypertension in the United States, 2003-2008</article-title>
          <source>Hypertension</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>1076</fpage>
          <lpage>80</lpage>
          <issue>6</issue>
          <volume>57</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Persell</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Minist&#233;rio da Sa&#250;de. Secretaria de Ci&#234;ncia, Tecnologia e Insumos Estrat&#233;gicos. Departamento de Assist&#234;ncia Farmac&#234;utica e Insumos Estrat&#233;gicos. Rela&#231;&#227;o nacional de medicamentos essenciais: Rename . 7&#350;.ed. Brasilia; 2010. (S&#233;rie B. Textos B&#225;sicos de Sa&#250;de).</mixed-citation>
        <element-citation publication-type="book">
          <source>Rela&#231;&#227;o nacional de medicamentos essenciais: Rename</source>
          <date>
            <year>2010</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Zeller A, Ramseier E, Teagtmeyer A, Battegay E. Patients' self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertens Res. 2008;31(11):2037-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Patients' self-reported adherence to cardiovascular medication using electronic monitors as comparators</article-title>
          <source>Hypertens Res</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>2037</fpage>
          <lpage>43</lpage>
          <issue>11</issue>
          <volume>31</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zeller</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ramseier</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Teagtmeyer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Battegay</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Al-Qazaz HKh, Hassali MA, Shafie AA, Sulaiman SA, Sundram S, Morisky DE. The eight-item Morisky Medication Adherence Scale MMAS: translation and validation of the Malaysian version. Diabetes Res Clin Pract. 2010 Nov;90(2):216-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The eight-item Morisky Medication Adherence Scale MMAS: translation and validation of the Malaysian version</article-title>
          <source>Diabetes Res Clin Pract</source>
          <date>
            <year>2010</year>
            <month>11</month>
          </date>
          <fpage>216</fpage>
          <lpage>21</lpage>
          <issue>2</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Al-Qazaz</surname>
              <given-names>HKh</given-names>
            </name>
            <name>
              <surname>Hassali</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Shafie</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Sulaiman</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Sundram</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Morisky</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. A&#241;ez CRR, Reis RS, Petroski EL. Vers&#227;o brasileira do question&#225;rio "estilo de vida fant&#225;stico": tradu&#231;&#227;o e valida&#231;&#227;o para adultos jovens. Arq Bras Cardiol. 2008;91(2):102-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vers&#227;o brasileira do question&#225;rio "estilo de vida fant&#225;stico": tradu&#231;&#227;o e valida&#231;&#227;o para adultos jovens</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>102</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>A&#241;ez</surname>
              <given-names>CRR</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Petroski</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Association between the 8-item Morisky Medication Adherence Scale (MMAS-8) and blood pressure control</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Non-adherence to treatment is an important and often unrecognized risk factor that contributes to reduced control of blood pressure (BP). OBJECTIVE: To determine the association between treatment adherence measured by a validated version in Portuguese of the 8-item Morisky Medication Adherence Scale (MMAS-8) and BP control in hypertensive outpatients. METHODS: A cross-sectional study was carried out with hypertensive patients older than 18 years, treated at six of the Family Health Strategy Units in Macei&#243; (AL), through interviews and home blood pressure measurements, between January and April 2011. Adherence was determined by MMAS-8 version translated for this study. The patients were considered adherent when they had a score equal to 8 at the MMAS-8. RESULTS: The prevalence of adherence among the 223 patients studied was 19.7%, while 34% had controlled BP (&gt; 140/90 mmHg). The average adherence value according to the MMAS-8 was 5.8 (&#177; 1.8). Adherent patients showed to be more prone (OR = 6.1, CI [95%] = 3.0 to 12.0) to have blood pressure control than those who reached mean (6 to &lt;8) or low values (&lt;6) at the adherence score. The Portuguese version of MMAS-8 was showed a significant association with BP control (p = 0.000). CONCLUSION: The diagnosis of non-adherent behavior through the application of MMAS-8 in patients using of antihypertensive medications was predictive of elevated systolic and diastolic BP.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Medication adherence</kwd>
        <kwd>blood pressure</kwd>
        <kwd>outpatients</kwd>
        <kwd>health systems</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <fn id="enda-body2">
          <label>
            <bold>Association between the 8-item Morisky Medication Adherence Scale (MMAS-8) and blood pressure control</bold>
          </label>
          <p>
            <bold>Alfredo Dias Oliveira-Filho; Jos&#233; Augusto Barreto-Filho; Sabrina Joany Felizardo Neves; Divaldo Pereira de Lyra Junior</bold>
          </p>
        </fn>
      </p>
      <p>Laborat&#243;rio de Ensino e Pesquisa em Farm&#225;cia Social (LEPFS), Curso de Farm&#225;cia, Universidade Federal de Sergipe, Departamento de Farm&#225;cia e Nutri&#231;&#227;o, Universidade Federal de Alagoas, Departamento de Medicina, Universidade Federal de Sergipe, SE - Brasil</p>
      <p>Mailing Address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND: </bold>Non-adherence to treatment is an important and often unrecognized risk factor that contributes to reduced control of blood pressure (BP).</p>
      <p><bold>OBJECTIVE: </bold>To determine the association between treatment adherence measured by a validated version in Portuguese of the 8-item Morisky Medication Adherence Scale (MMAS-8) and BP control in hypertensive outpatients. </p>
      <p><bold>METHODS: </bold>A cross-sectional study was carried out with hypertensive patients older than 18 years, treated at six of the Family Health Strategy Units in Macei&#243; (AL), through interviews and home blood pressure measurements, between January and April 2011. Adherence was determined by MMAS-8 version translated for this study. The patients were considered adherent when they had a score equal to 8 at the MMAS-8.</p>
      <p><bold>RESULTS: </bold>The prevalence of adherence among the 223 patients studied was 19.7%, while 34% had controlled BP (&gt; 140/90 mmHg). The average adherence value according to the MMAS-8 was 5.8 (&#177; 1.8). Adherent patients showed to be more prone (OR = 6.1, CI [95%] = 3.0 to 12.0) to have blood pressure control than those who reached mean (6 to &lt;8) or low values (&lt;6) at the adherence score. The Portuguese version of MMAS-8 was showed a significant association with BP control (p = 0.000). </p>
      <p><bold>CONCLUSION:</bold> The diagnosis of non-adherent behavior through the application of MMAS-8 in patients using of antihypertensive medications was predictive of elevated systolic and diastolic BP. </p>
      <p><bold>Keywords:</bold> Medication adherence; blood pressure; outpatients; health systems.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>In patients with systemic arterial hypertension (SAH), non-adherence is an important and often unrecognized risk factor that contributes to the reduced control of blood pressure (BP), leading to the development of other cardiovascular diseases such as heart failure, coronary artery disease, renal failure and cerebrovascular accident<sup>1</sup>.</p>
      <p>Studies comprehending five decades have estimated that 20% to 50% of patients do not take their medications as prescribed<sup>2</sup>. According to the World Health Organization (WHO), in developed countries, non-adherence of patients with chronic diseases is around 50%, being probably higher in developing countries<sup>3</sup>. </p>
      <p>Although the prevalence and implications of non-adherence on clinical outcomes have been increasingly acknowledged, the true impact of measures known to be effective in BP control, such as cost-free pharmacotherapy given at outpatient clinics, provided by the Brazilian Public Health System (SUS), particularly through the Family Health Strategy, is still ignored<sup>4</sup>. Thus, the systematic diagnosis of non-adherence is crucial to investigate its impact on clinical outcomes. </p>
      <p>In this context, the most widely used method of adherence assessment is the Morisky Medication Adherence Scale (MMAS 4- item version)<sup>5</sup>. Recently, a new eight-item scale (MMAS-8), which has greater reliability (a = 0.83 vs. = 0.61)<sup>6</sup>, created with the objective of determining adherence to antihypertensive treatment, was developed from the MMAS-4 and supplemented with additional items designed to address several aspects of adherence behavior. In Brazil, studies evaluating non-adherence with the new scale are still recent and scarce<sup>7</sup>. </p>
      <p>The present study aimed to determine the relationship between adherence measured from a validated version in Portuguese of the MMAS-8 and BP control in hypertensive outpatients treated by the Family Health Strategy teams. </p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Study design, setting and period</bold>
      </p>
      <p>A cross-sectional study was carried out by applying a structured interview to hypertensive patients treated by the Family Health Strategy teams. </p>
      <p>The interviews occurred in six Family Health Units (USF) of Maceio linked to the second edition of Health Tutorial Education Program (PET-Saude II) between January and April 2011. </p>
      <p>
        <bold>Study Population</bold>
      </p>
      <p>We selected patients with confirmed diagnosis of hypertension who were treated at the USF, aged 18 or older and who used antihypertensive medications. Patients with secondary hypertension confirmed by medical records or who had purchased at least one antihypertensive drug in the thirty days preceding the interview were excluded. This exclusion criterion was aimed to eliminate the interference of the cost of drugs, one of the major predictive factors of nonadherence<sup>8</sup>. </p>
      <p>
        <bold>Interviews and assessed variables</bold>
      </p>
      <p>The interviews were carried out in the patients' houses, by previously trained students of pharmaceutical sciences who were members of the PET-Health and who were monitored during the home visit by a health agent of the USF. The following variables were investigated: gender, age, schooling, regular physical activity, alcohol consumption, smoking, drugs, amount of medication, time of use of antihypertensive drugs, systolic blood pressure (SBP), diastolic blood pressure (DBP) and blood pressure control, characterized by BP values &lt; 140/90 mmHg, respectively. </p>
      <p>Patients with uncontrolled blood pressure were classified as patients with resistant or pseudoresistant hypertension, according to the literature<sup>9-11</sup>. The values of systolic (SBP) and diastolic (DBP) blood pressure were obtained by the mean of two blood pressure measurements, carried out by the research team during the visit, according to the guidelines established in the VI Brazilian Guidelines for the Treatment of Hypertension<sup>9</sup>, using a mercury sphygmomanometers calibrated with a minimum interval of 5 minutes between each measurement. To reduce the influence of the white-coat effect - defined as a persistently increased blood pressure at the medical office, compared with measurements at home or after 24-hour ambulatory blood pressure monitoring (ABPM) - on BP values, the measurements were taken at the patients' homes<sup>12,13</sup>. </p>
      <p>Adherence was measured using the eight-item Morisky Medication Adherence Scale (MMAS-8)<sup>6</sup>, translated into Brazilian Portuguese (<xref ref-type="fig" rid="ct1-body2">chart 1</xref>) and validated for the present study. To obtain conceptual equivalence, the MMAS-8 was translated in accordance with the recommendations for translation and cultural adaptation of Beaton et al.<sup>14</sup>, Wild et al.<sup>15</sup>, which require the translation and back-translation by bilingual translators, some of which are independent. After evaluation and approval by the author of the scale, the translated version was tested in a group of 20 patients with hypertension to check for understanding of the questions in accordance with its original meaning. The questions were understood identically by all, and subsequent alterations were not considered necessary. </p>
      <fig id="ct1-body2">
        <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gf01-en.jpg"/></fig>
      <p>The MMAS-8, an update with greater sensitivity of the four-item scale published in 1986 and considered the most commonly used self-reporting method to determine adherence, contains eight questions with closed dichotomous (yes / no) answers, designed to prevent the bias of positive responses from patients questions asked by health professionals, by reversing the responses related to the interviewee's adherence behavior<sup>6,16</sup>. Thus, each item measured a specific adherence behavior, with seven questions that must be answered negatively and only one positively, with the last question being answered according to a scale of five options: never, almost never, sometimes, often, and always. </p>
      <p>The degree of adherence was determined according to the score resulting from the sum of all the correct answers: high adherence (eight points), average adherence (6 to &lt; 8 points) and poor adherence (&lt; 6 points)<sup>17</sup>. In this study, patients were considered adherent when they had a score equal to eight in the MMAS-8.</p>
      <p>To assess the internal consistency, we used the item-total correlation and Cronbach's alpha. </p>
      <p>
        <bold>Sample size</bold>
      </p>
      <p>Considering the original study by Morisky et al., where 16% of patients achieved a score of 8 at the MMAS-8, as well as absolute accuracy of 5% and confidence interval of 95%, a sample of 207 individuals was determined. In order to correct any losses and provide a better breakdown of the independent variables, the sample size was adjusted by a proportional factor of 1.25. Thus, the sample size for this study was established at 230 patients. The number of patients needed to assess the internal consistency was considerably lower, being obtained by Non-Parametric Approach to Calculate Sample Size Based on Assessment Questionnaires or Scales in Healthcare Area, developed by Couto Jr.<sup>18</sup>, which estimates the sample size by the number of items and categories of the data collection instrument. </p>
      <p>
        <bold>Statistical Analysis</bold>
      </p>
      <p>Data analysis was performed using SPSS software, release 12. Statistical analyzes involved: descriptive analyzes, the Kolmogorov-Smirnov test to check the normality of continuous variables, chi-square and Kruskal-Wallis test to test the relationship between adherence and other independent variables, and binary logistic regression. All variables with p &lt; 0.25 in the bivariate analysis were included in the initial model of the multivariate analysis. Then the variables that showed a higher value of p were removed, one by one, until only variables with statistical significance remained in at least one of the categories of therapeutic adherence. The level significance was set at &#945; &lt; 5%. </p>
      <p>
        <bold>Ethical Aspects</bold>
      </p>
      <p>The study was approved by the Ethics Committee in Research of Universidade Federal de Alagoas on 11/06/2009, protocol# 010186/2009-01. Data were collected only after the informed consent had been signed by all patients. </p>
      <p>
        <bold>Results</bold>
      </p>
      <p>We selected 231 patients, eight of whom declined to participate in the study (refusal rate = 3.5%). The mean age of patients was 57.18 years (&#177; 12.7), with a minimum age of 27 and maximum of 85 years, and the majority (70.9%) of them were females. Only 46 (20.6%) patients practiced some regular physical activity. Smoking and alcohol consumption were reported by 10.3% and 18.8% of patients, respectively. None of the variables investigated was associated with adherence or blood pressure control (<xref ref-type="table" rid="en_aop05012tab01m-body2">Tables 1</xref> and <xref ref-type="table" rid="en_aop05012tab02m-body2">2</xref>).</p>
      <p content-type="asset">
        <table-wrap id="en_aop05012tab01m-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gt01-en.jpg"/></table-wrap>
      </p>
      <p content-type="asset">
        <table-wrap id="en_aop05012tab02m-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gt02-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Therapeutic adherence and blood pressure control</bold>
      </p>
      <p>Only 34.1% of patients had blood pressure under control. The rate of therapeutic adherence (MMAS-8 = 8, high adherence) was 19.7%. The mean adherence value according to the MMAS-8 was 5.8 (&#177; 1.8). Among patients considered non-adherent, 33.2% had mean adherence, and 47.1%, low adherence. According to logistic regression analysis, patients who reached maximum values in the MMAS-8 showed to be more likely (OR = 6.1, [95%] CI = 3.0 to 12.0) to have blood pressure control than those who attained mean (6 to &lt;8) or low (&lt;6) values. The association of BP control (p = 0.000) and mean SBP and DBP (p = 0.002510 and p = 0.000135, respectively) with the degree of adherence can be seen in <xref ref-type="table" rid="en_aop05012tab03m-body2">Table 3</xref>. </p>
      <p content-type="asset">
        <table-wrap id="en_aop05012tab03m-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gt03-en.jpg"/></table-wrap>
      </p>
      <p>Additionally, these associations can be used to investigate a suspected sub-optimal adherence to therapy in patients with uncontrolled BP: 75.6% of patients with uncontrolled BP did not adhere to antihypertensive treatment, while 33.3% of patients with BP under control were nonadherent. </p>
      <p>
        <bold>Medication use</bold>
      </p>
      <p>The mean number of drugs prescribed per patient was 3.15 (&#177; 1.63, 3.11 among adherent, and 3.16 among non-adherent patients) and the mean number of antihypertensive drugs per patient was 1.61 (&#177; 0.65; 1.51 and 1.67 in adherents and non-adherents, respectively). The most frequently prescribed medications were hydrochlorothiazide (to 53.3% of patients), captopril (49.9%), propranolol (14.3%), enalapril (12.1%), amlodipine (11.2%), atenolol (8.5%) and losartan (4.9%). Most patients (52.5%) had been using the same anti-hypertensive drug therapy for five years or more, 20.2% had used the same treatment for three or four years, 12.6% had used it for one to two years; 8 5% from six months to a year, and 6.3%, for less than six months. </p>
      <p>Antihypertensive monotherapy was prescribed to 47.1% of patients; 45.3% were taking two antihypertensive drugs and 7.1% were using three or more drugs, one of which was a diuretic. While 36.2% of patients on monotherapy and 36.6% of patients taking two drugs had controlled blood pressure (<xref ref-type="table" rid="en_aop05012tab02m-body2">Table 2</xref>), only 5.9% of patients using three or more antihypertensive drugs had the same outcome (p = 0.038).</p>
      <p>Among patients with uncontrolled blood pressure, 2.7% (1.8% of total patients) were both adherents and users of triple antihypertensive therapy containing a diuretic, characterizing resistant hypertension. The other patients who had elevated BP values were divided as follows: 8.2% did not adhere to triple therapy with a diuretic, 8.8% were adherent, but used one or two antihypertensive drugs, and 80.3 % were nonadherent and used one or two antihypertensive drugs (<xref ref-type="table" rid="en_aop05012tab04m-body2">Table 4</xref>). </p>
      <p content-type="asset">
        <table-wrap id="en_aop05012tab04m-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gt04-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Scale reliability</bold>
      </p>
      <p>The corrected item-total correlation resulted in a value &lt; 0.20 for item 3, which was low, although significantly different from zero. However, the Cronbach's alpha values resulting from the exclusion of each item were lower, without exception, than the resulting coefficient (&#945; = 0.69), indicating that the inclusion of item 3 did not affect the instrument reliability (<xref ref-type="table" rid="en_aop05012tab05m-body2">Table 5</xref>). </p>
      <p content-type="asset">
        <table-wrap id="en_aop05012tab05m-body2">
          <graphic xlink:href="1678-4170-abc-99-01-0649-00053-gt05-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>Cardiovascular Diseases (CVD), of which main risk factor is hypertension<sup>19,20</sup>, are a major cause of mortality both worldwide and in Brazil, where they accounted for 32% of deaths in individuals over 30 years in 2005<sup>21</sup>. Several BP control measures have been tested<sup>22,23</sup>; however, not even the strong evidence that several antihypertensive drug treatments are effective in reducing cardiovascular morbidity and mortality rates mean appropriate blood pressure (BP) control, due to poor adherence to treatment<sup>9,24</sup>. Studies of the Brazilian population indicate a BP control of 20% to 60%<sup>20,25-27</sup>, within the same range of BP control observed in our study.</p>
      <p>According to literature, poor adherence affects the clinical outcome and quality of life, causing adverse outcomes such as increased morbimortality and healthcare costs<sup>28</sup>. In the treatment of hypertension, its first consequence is the failure in BP control; several studies have shown this association, also found in our study, in which significantly lower systolic and diastolic pressures were observed among patients with a high degree of adherence<sup>6,29,30</sup>. </p>
      <p>The dichotomous categorization of adherence in adherent vs. nonadherent patients was based, as in the original study, on the association between the scale and blood pressure control. However, in this study, only those patients with high adherence (score of 8) were considered adherent, as this group was associated with blood pressure control (<xref ref-type="table" rid="en_aop05012tab03m-body2">Table 3</xref>). In a study by Morisky et al.<sup>6</sup> patients with high and medium adherence were considered adherent. </p>
      <p>Although the application protocols are identical, the results suggest that the interpretation of the score is different, making the care target to be focused on improving adherence behavior not only in patients with a low level of adherence, but also those with a medium degree. In our study, 65.1% of patients with high adherence and 37.0% of patients with medium degree of adherence had controlled BP, while in the original study the difference between both groups was lower (56.7% and 44.8%, respectively). However, both studies showed a lower percentage of patients with a high degree of adherence, less than 20%. </p>
      <p>Initially, the use of the first Morisky adherence scale (MMAS-4) allowed not only to determine non-adherent patients at risk of not achieving BP control, but also to know some causes of poor adherence. As new self-reporting methods were developed, its use as a screening tool in clinical practice has become an increasingly desirable characteristic. In the treatment of patients with uncontrolled hypertension, for instance, the investigation of the probable causes should always consider the non-adherence. In our study, the translated version of MMAS-8 identified a large proportion of non-adherent patients among those with uncontrolled blood pressure, more than two-fold the number of patients with BP under control. </p>
      <p>According to the World Health Organization, 51% of patients with hypertension in the United States adhere to treatment, while in China, the rate of adherence among these patients is 43%<sup>3</sup>. Hyre et al.<sup>29</sup>, in a study with MMAS-8 applied to patients with hypertension, found that 35.6% of patients adhered completely to the prescription. However, in such studies, the cost of drugs was a factor that hindered patient adherence, whereas the patients included in this study had free access to anti-hypertensive drugs. The cost of drugs is the most widely studied<sup>8,31</sup> predictive factor of nonadherence, and its importance in the compliance to antihypertensive treatments have been demonstrated in studies involving large numbers of patients<sup>32,33</sup>. Nevertheless, the rate of adherents observed in the current investigation was lower than that in the aforementioned studies, indicating that free access to antihypertensive treatment itself did not lead to satisfactory levels of adherence.</p>
      <p>According to two major studies reviewing therapeutic adherence, one of which covers fifty years of research on the topic, adherence has no apparent association with demographic characteristics - such as gender, age, socioeconomic status and ethnic group - and disease severity<sup>2,31</sup>. Some predictors, however, have been consistently associated with poor adherence, among which we highlight the complexity of the regimen, the treatment of asymptomatic disease, the presence of psychological problems like depression and medication side effects<sup>34</sup>. Except for the psychological problems, which were not considered in our study, other factors had little or no influence on the adherent behavior of the studied patients. The most relevant component of the therapeutic regimen complexity is the number of prescribed drugs<sup>34</sup>. However, no association was found between the number of drugs used and their dosage, and treatment adherence. </p>
      <p>As for the predictors of BP control, recently, the ALLHAT study<sup>35</sup> - a randomized clinical trial involving a large number of patients aimed to assess the control of hypertension and the effects of antihypertensive drugs on clinical outcomes - identified higher basal BP, Black ethnicity and age as the main predictors of lack of BP control. Among the additional causes are the female gender, diagnosis of diabetes, obesity, previous antihypertensive therapy and left ventricular hypertrophy<sup>35</sup>. Of all these factors, only age, gender, use of oral hypoglycemic agents and duration of antihypertensive treatment were considered in this investigation. Nevertheless, the only variable related to poor BP control, as well as non-adherence, was the use of three or more antihypertensive agents.</p>
      <p>One hypothesis for this finding is that even among patients considered adherent by the MMAS-8, there may be incorrect drug use. The translated and validated adherence scale used in this study, although it contains several questions related to specific non-adherent behavior, does not address issues such as time and method of using, which may explain the lack of association between the use of three or more antihypertensive drugs with an inadequate adherence, but the existence of an association between the number of these drugs and lack of BP control. Another hypothesis is the highest degree of severity of these patients' clinical condition, implying greater difficulty in controlling BP. Moreover, factors such as the quality of pharmacotherapy practiced within the Public Health System should be investigated for the accurate identification of the relevant causes of uncontrolled hypertension. </p>
      <p>In clinical practice, patients adherent and non-responsive to the triple optimized antihypertensive therapy that includes a diuretic agent characterize cases of resistant hypertension<sup>9-11</sup>. According to this concept, 1.8% of the interviewed patients had resistant hypertension. The prevalence of resistant hypertension, which is generally not known, has recently been estimated in the United States, representing approximately 8.9 % of hypertensive patients<sup>36</sup>. In this situation it is necessary to evaluate the presence of factors that hinder BP control, such as excessive sodium intake, alcohol consumption, obesity, use of drugs with potential to raise blood pressure, obstructive sleep apnea syndrome and secondary forms of hypertension, and correct these factors<sup>9</sup>. </p>
      <p>In turn, the term "pseudoresistant hypertension" refers to the lack of BP control in patients with appropriate treatment exposed to other factors that contribute to raise BP measurements, such as inappropriate measurement technique, white-coat effect and <italic>low adherence</italic><sup>10,11</sup>. The choice of the active ingredients or dose, the first of the causes of pseudoresistant hypertension was not analyzed individually in our study, but considered in accordance with the antihypertensive and dose ranges contained in the National List of Essential Medications (Rename)<sup>37</sup>. Thus, no therapeutic choice was considered inappropriate. Therefore, all patients with uncontrolled BP who did not have resistant hypertension were classified as having pseudoresistant hypertension, found in 64.1% of the patients. Pseudoresistant hypertension caused by poor adherence accounted for 58.3% of patients in the study. It is important to consider that this value could be even higher, as the self-reporting methods have as major limitation the underestimation of the number of non-adherent individuals.</p>
      <p>In turn, the self-reporting methods to determine adherence, in contrast with techniques such as quantification of drugs and their metabolites in body fluids, drug electronic monitoring (Medication Event Monitoring System - MEMS) or counting the pills unused by the patient, are simple, rapid, noninvasive, and economical, and can provide a real-time opinion about the adherence behavior of patients and potential reasons for non-adherence<sup>38</sup>. </p>
      <p>Although these methods are subject to bias, as the overestimation of adherence, the constant improvement of these instruments and their validation studies in different populations have increased their adoption in clinical practice<sup>6</sup>.</p>
      <p>The internal consistency measured by Cronbach's alpha (0.69) was lower than that obtained by Morisky et al.<sup>6</sup> in patients with hypertension (0.83), but slightly higher than the internal consistency values observed in studies with scale translation into other languages published so far<sup>39</sup>. According to A&#241;ez et al.<sup>40</sup>, an alpha value &gt; 0.5 have been considered acceptable in questionnaire validation studies, a value which was adopted by Al-Qazaz in a cross-cultural adaptation study of the MMAS-8 into Malaysian<sup>39</sup>. Although a number of questions showed a lower item-total correlation, as is the case of questions 3, 4 and 7, it was observed that the removal of these questions would not increase the instrument's alpha, which would make the exclusion unjustified, de-characterizing the instrument. </p>
      <p>In the present study, MMAS-8 showed good potential as a screening tool in clinical practice to identify non-adherent patients and those at risk of uncontrolled BP, considering the reliability of the translated version, its significance association with the BP control and the SBP and DBP values, its simplicity and validation in other studies with hypertensive patients. In the SUS context, this scale can be an important tool for hypertension control. Another broader investigation to determine adherence in patients using antihypertensive drugs supplied free of cost by the government is being carried out. </p>
      <p>
        <bold>Limitations</bold>
      </p>
      <p>In this study, some predictors of non-adherence - such as depression - and of absence of blood pressure control - such as ethnicity and higher basal levels of systolic and diastolic BP - were not investigated as variables of interest or even considered in the process of patient inclusion. The classification of patients with uncontrolled hypertension according to the pseudo-resistant hypertension type is also subject to interpretation bias, since despite the careful observation of other causal factors of pseudo-resistant hypertension, and efforts to reduce or control some of them, such as white-coat effect and inadequate measure of blood pressure, the only cause that can be determined with precision was therapy adherence.</p>
      <p>
        <bold>Final considerations</bold>
      </p>
      <p>The diagnosis of non-adherent behavior through the use of the new 8-item Morisky Medication Adherence Scale (MMAS-8) in patients treated with antihypertensive drugs was a predictive factor of elevated systolic and diastolic blood pressure. Considering that non-adherence is a major cause of uncontrolled blood pressure, the use of self-report scales related to BP is a simple and inexpensive measure to assist the clinical treatment of patients with hypertension. </p>
      <p>
        <bold>Acknowledgements</bold>
      </p>
      <p>We thank the support of Secretaria Municipal de Sa&#250;de de Macei&#243;; of the multidisciplinary teams of Unidades de Sa&#250;de da Fam&#237;lia; the Health Tutorial Education Program team of UFAL; Dr. Donald E. Morisky, from the University of California, Los Angeles (UCLA). We also thank the careful data collection performed by pharmacists Cl&#225;udia C. N&#243;brega de Farias Ayres, Fernanda Bertazolli Albieri, Hugo A. Leite Mota Vasconcelos, Mirela Quirino de Almeida, Morgana R. Maciel Cabral Davino, Natyelle M. Santos Macedo and all the patients that participated in this study.</p>
      <p>
        <bold>Potential Conflict of Interest </bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding </bold>
      </p>
      <p>This study was partially funded by Funda&#231;&#227;o de Apoio &#224; Pessoa do Estado de Alagoas (FAPEAL).</p>
      <p>
        <bold>Study Association </bold>
      </p>
      <p>This article is part of the thesis of doctoral submitted by Alfredo Dias de Oliveira Filho (N&#250;cleo de P&#243;s-gradua&#231;&#227;o em Medicina - UFS), from Faculdade de Medicina e Faculdade de Ci&#234;ncias Farmac&#234;uticas Ribeir&#227;o Preto - USP.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
